Edasalonexent
- Generic Name
- Edasalonexent
- Drug Type
- Small Molecule
- Chemical Formula
- C31H42N2O3
- CAS Number
- 1204317-86-1
- Unique Ingredient Identifier
- AF3Z6434KS
- Background
Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
Astria Therapeutics Advances Navenibart for HAE with Phase 3 Trial
• Astria Therapeutics is initiating the ALPHA-ORBIT Phase 3 trial to evaluate navenibart for hereditary angioedema (HAE) with flexible dosing.
• The trial will assess the efficacy and safety of navenibart administered every 3 or 6 months over a 6-month period in HAE patients.
• Positive Phase 1b/2 results showed a 90-95% reduction in mean monthly attack rate and up to 67% attack-free rate with navenibart.
• ALPHA-ORBIT's design incorporates feedback from regulators and aims for global registration, potentially making navenibart a first-choice HAE therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath